Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TATA-box binding protein associated factor 9 (TAF9) is a highly conserved subunit of the transcription factor IID (TFIID) complex, which is crucial for the initiation of transcription by RNA polymerase II. TFIID consists of the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs), including TAF9. TAF9 acts as a coactivator in transcriptional regulation, participating in both activation and repression of gene transcription, in part through direct interactions with transcriptional activators such as p53 and VP16, as well as several other TAFs and general transcription factors. TAF9 is essential for cell viability and gene expression, forming part of several chromatin-associated complexes involved in promoter recognition and pre-initiation complex assembly. Its ability to stabilize and regulate p53 links it to apoptosis and potential roles in cancer biology. No approved therapeutic drugs specifically target TAF9; direct targeting would likely pose significant safety concerns due to its central role in general transcription[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TATA-box binding protein associated factor 9 (TAF9).